Caplin Point Laboratories
CAPLIPOINT · Pharma > Pharmaceuticals & Drugs · Chairman: C C Paarthipan · MD: Sridhar Ganesan · Listing date: June 23, 2014 · Employees: 1675 · Chennai · http://www.caplinpoint.net

Stock Price vs Company Growth
1d
0.4%
1w
0.5%
1m
3.8%
3m
11.5%
6m
48.9%
1y
59.4%
5y
43.8%
10y
37.6%
all
47.5%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,944 0.4%
1,759
2,175
Company Overview

Sales
1,831 Cr
Growth: 14.8%
Profit after Tax
494 Cr
Growth: 3.3%
Mid Cap
14,773 Cr
P/E: 30.1x
Industry P/E: 36.0x
Fundamentals

Sales (Cr) ₹ 1,831
Growth 14.8%
EBITDA 33.0%
P/S 8.1x
Dividend 0.5%
P/E 30.1x
Book Value ₹ 338
PEG Ratio 2.0x
ROE 20.7%
P/B 5.7x
Shareholding Pattern

Institutions
Promoters
P Vijayalakhsmi
23.64 %
Paarthipan C C
18.73 %
Ashok Gorkey Partheeban
11.96 %
Partheeban Vivek Siddarth
11.9 %
May India Property Private Limited
2.8 %
Others
Iepf
2.46 %
Visalatchi
2.22 %
Suresh Kumar Agarwal
1.32 %
Ashish Kacholia
1.16 %
Llp
0.7 %
Increase    Decrease    No change
Company Profile Detailed

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
Investors (51)
Followers (27)